Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting

Maasoumy, Benjamin; Port, Kerstin; Markova, Antoaneta Angelova; Serrano, Beatriz Calle; Rogalska-Taranta, Magdalena; Sollik, Lisa; Mix, Carola; Kirschner, Janina; Manns, Michael P.; Wedemeyer, Heiner; Cornberg, Markus
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Background: HCV protease inhibitors (PIs) boceprevir and telaprevir in combination with PEG-Interferon alfa and Ribavirin (P/R) is the new standard of care in the treatment of chronic HCV genotype 1 (GT1) infection. However, not every HCV GT1 infected patient is eligible for P/R/PI therapy. Furthermore phase III studies did not necessarily reflect real world as patients with advanced liver disease or comorbidities were underrepresented. The aim of our study was to analyze the eligibility and safety of P/R/PI treatment in a real world setting of a tertiary referral center. Methods: All consecutive HCV GT1 infected patients who were referred to our hepatitis treatment unit between June and November 2011 were included. Patients were evaluated for P/R/PI according to their individual risk/benefit ratio based on 4 factors: Treatment-associated safety concerns, chance for SVR, treatment urgency and nonmedical patient related reasons. On treatment data were analyzed until week 12. Results: 208 patients were included (F3/F4 64%, mean platelet count 169/nl, 40% treatment-naïve). Treatment was not initiated in 103 patients most frequently due to safety concerns. 19 patients were treated in phase II/III trials or by local centers and a triple therapy concept was initiated at our unit in 86 patients. Hospitalization was required in 16 patients; one patient died due to a gastrointestinal infection possibly related to treatment. A platelet count of <110/nl was associated with hospitalization as well as treatment failure. Overall, 128 patients were either not eligible for therapy or experienced a treatment failure at week 12. Conclusions: P/R/PI therapies are complex, time-consuming and sometimes dangerous in a real world setting, especially in patients with advanced liver disease. A careful patient selection plays a crucial role to improve safety of PI based therapies. A significant number of patients are not eligible for P/R/PI, emphasizing the need for alternative therapeutic options.


Related Articles

  • Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. del Carmen Manzano-Robleda, María; Ornelas-Arroyo, Victoria; Barrientos-Gutiérrez, Tonatíuh; Méndez-Sánchez, Nahum; Uribe, Misael; Chávez-Tapia, Norberto C. // Annals of Hepatology: Official Journal of the Mexican Associatio;Jan/Feb2015, Vol. 14 Issue 1, p46 

    Background. Treatment of hepatitis C virus (HCV) infection with newer direct-acting antivirals is unrealistic in some countries because of the lack of availability. Aim. Assess benefits and harms of boceprevir (BOC) and telaprevir (TLV) in treatment of genotype 1 HCV infection, and identifying...

  • Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience. Mangia, Alessandra; Cenderello, Giovanni; Orlandini, Alessandra; Piazzolla, Valeria; Picciotto, Antonio; Zuin, Massimo; Ciancio, Alessia; Brancaccio, Giuseppina; Forte, Paolo; Carretta, Vito; Zignego, Anna Linda; Minerva, Nicola; Brindicci, Gaetano; Marignani, Massimo; Baroni, Gianluca Svegliati; Bertino, Gaetano; Cuccorese, Giuseppe; Mottola, Leonardo; Ripoli, Maria; Pirisi, Mario // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Background: Triple therapy including Telaprevir or Boceprevir still represents in many European countries the standard of care for patients with Hepatitis C Virus genotype 1 infection. The number of patients who received this treatment resulted generally lower than expected. We investigated,...

  • Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients. Blázquez-Pérez, Antonio; San Miguel, Ramón; Mar, Javier // PharmacoEconomics;Oct2013, Vol. 31 Issue 10, p919 

    Background: Chronic hepatitis C is the leading cause of chronic liver disease, representing a significant burden in terms of morbidity, mortality and costs. A new scenario of therapy for hepatitis C virus (HCV) genotype 1 infection is being established with the approval of two effective HCV...

  • Boceprevir.  // AHFS Consumer Medication Information;Oct2017, p1 

    Boceprevir is used along with two other medications (ribavirin [Copegus, Rebetol] and peginterferon alfa [Pegasys]) to treat chronic hepatitis C (an ongoing viral infection that damages the liver) in people who have not yet been treated for this condition or whose condition did not improve when...

  • Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. D'Ambrosio, Roberta; Aghemo, Alessio; Colombo, Massimo // Biologics: Targets & Therapy;2012 Part 2, Vol. 6, p363 

    Telaprevir (TVR) is an orally available protease inhibitor of the hepatitis C virus that in association with pegylated interferon and ribavirin (PR) was shown to improve the rates of sustained virological response and potentially reduce treatment duration in adult patients with chronic hepatitis...

  • Do direct-acting antivirals improve treatment outcomes in genotypes 2, 3 and 4? Cooksley, W. Graham E.; Crawford, Darrell H. G.; Bowden, D. Scott // Hot Topics in Viral Hepatitis;2011, Vol. 7 Issue 22, p17 

    Since the rates of sustained virological response (SVR) using pegylated interferon alpha (PEG-IFN-α) and ribavirin in subjects infected with hepatitis C virus (HCV) genotype 2/3 (G2/G3) are around 80%, it is difficult to see advantages to adding current off-label protease inhibitors...

  • Low SVR Rates in Clinical Practice for Treating Genotype 1 Chronic Hepatitis C with Protease Inhibitors Boceprevir and Telaprevir. Dubin, Perry; Sclair, Seth; Rico, Rene; Boehme, Amelia; Chen, Emerson; Martin, Paul; Lee, William // Digestive Diseases & Sciences;Jan2015, Vol. 60 Issue 1, p272 

    No abstract available.

  • Telaprevir.  // AHFS Consumer Medication Information;Oct2017, p1 

    Telaprevir is used along with two other medications (ribavirin [Copegus, Rebetol] and peginterferon alfa [Pegasys]) to treat chronic hepatitis C (an ongoing viral infection that damages the liver) in people who have not yet been treated for this condition or whose condition could not...

  • New protease inhibitors showing promise for HIV/HCV coinfection. Brock, Jeff // Infectious Disease News;Aug2013, Vol. 26 Issue 8, p13 

    The article reports that the drugs boceprevir known as Victrelis by Merck and telaprevir known as Incivek by Vertex Pharmaceuticals are new treatments for chronic hepatitis C virus infections (HCV), a major cause of morbidity and mortality in patients with the human immunodeficiency virus (HIV).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics